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The expeditious diagnosis of acute myocardial infarction (AMI) at the time of patient presentation allows for optimal treatment and outcome (1) . However, the time interval between onset of symptoms and diagnosis varies, and unequivocal electrocardiographic evidence for infarctions is not always available. Recent work has examined the efficacy of creatine kinase MB (CK-MB) (2, 3) , CK-MB isoforms (3), myoglobin (2) , and troponins (4, 5) at initial presentation, and serially thereafter, for supporting the diagnosis of AMI.
The may have greater sensitivity than total CK activity for diagnosing AMI, and more importantly, may provide useful prognostic information in patients with AMI (9) . Thus, we investigated the diagnostic accuracies of IL-6, which plays a key role in the acute-phase response, and C-reactive protein (CRP) as first-look indicators of AM!. We measured these markers in the blood sample obtained at initial presentation and compared these with CK-MB, myoglobin, and troponin I measured in the same initial sample.
We studied 129 consecutive patients who presented to the emergency department of the Cleveland Clinic Foundation with chest pain and were evaluated for the presence of AMI. Final diagnosis was based primarily on chest pain, increase in CK-MB mass [>4.0 L and relative index >5%] during the first 24 h after presentation, and (or) diagnostic electrocardiographic changes. CK-MB was measured at 8-h intervals for the first 24 h after presentation. Echocardiography and cardiography at the time of cardiac catheterization were also used in assessing the presence of a new infarct. The biochemical markers other than CK-MB were measured in excess sera, and the results were not made available for clinical diagnosis. The study protocol conformed to the requirements of the Cleveland Clinic Foundation Institutional Review Board. CK-MB was determined by immunoassay with the IMx (Abbott Laboratories, Abbott Park, IL). Troponin I and myoglobin were determined by immunoassay with the Stratus II (Baxter Diagnostics, Deerfield, IL) with reagents provided by the manufacturer;
CRP was determined by rate immunonephelometry with an Array (Beckman Instruments, Brea, CA); and IL-6 was measured by an ELISA kit (R&D Systems, Minneapolis, MN).
Of the 129 patients studied, 31 were found to have had an AMI and 98 were not. The interval from the onset of symptoms to presentation to the emergency department . The values for CK-MB, troponin I, and myoglobin were significantly higher (Mann-Whitney test, P <0.05) in patients with AMI than in those without AMI, but neither IL-6 nor CRP differed significantly between these groups. Data from Q-wave and non-Q-wave infarctions were not significantly different for IL-6 and CRP. Samples whose CRP concentrations were less than the assay lower detection limit (9.0 gfL) were assigned the value of 9.0 gfL for data analysis.
We calculated the sensitivities and specificities for each analyte over the range of values obtained. CK-MB was included in the analysis for comparison because its initial value was not used by itself for the routine enzymatic diagnosis of AMI in this population but rather the entire set of values obtained during the initial 24 h. The receiveroperator characteristic (ROC) curves generated from these data by an expert system described previously (10) are shown in Fig. 1 . The ROC curve for CRP follows closely the diagonal, demonstrating little diagnostic information. IL-6 shows somewhat better performance, as do myoglobin and troponin I. CK-MB demonstrates the greatest area under the curve, as determined according to the method of Hanley and McNeil (11) . The area under the IL-6 ROC curve (mean ± SE: 0.626 ± 0.059) was significantly (Wilcoxon W statistic, P <0.05) less than that observed for CK-MB (0.820 ± 0.048) but not significantly different from that for CRP (0.520 ± 0.059), myoglobin (0.734 ± 0.054), or troponin I (0.683 ± 0.063).
The largest number of correctly classified cases, based on all possible combinations of biochemical marker values, was achieved with the diagnostic criterion of CK-MB >7 g/L or tropomn I >7.2 gfL. This criterion demonstrated a sensitivity of 0.62 and a specificity of 0.99, corresponding to a positive predictive value of 0.94 and a negative predictive value of 0.90. Neither IL-6 nor CRP contributed incremental predictive value.
The acute-phase response to AM! is substantial, and measurement of IL-6 may have prognostic value in this clinical setting (9) , perhaps because of a relationship between the extent of the infarct and the magnitude of the acute phase response, but this has yet to be shown conclusively. Nonetheless, the IL-6 response has not been evaluated extensively in the presentation of evolving AMI. Although measurement of the cytokine response is an alternative to measuring cellular component leakage in AMI, our data indicate it is not of incremental diagnostic value at the time of presentation relative to more tradi- in the population studied. The fact that IL-6 and CRP values were not significantly different in the AMI and non-AMI groups could suggest both a lack of sensitivity of the acute-phase response at presentation and the presence of other inflammatory conditions in this population. This study population included patients with various elapsed times since the onset of symptoms and thus represents an actual emergency department experience involving sequential patient evaluations. The relative performance of the markers studied might be different in other populations. We emphasized, moreover, that this study evaluated initial presentation sampling and did not address serial sampling during the hours after presentation.
The most important clinical application of plasma/serum ferritin concentrations in combination with hemoglobin concentrations is as a diagnostic tool for iron-deficiency anemia, with ferritin concentrations believed to be one of the most reliable indices of body iron stores. Values <10-12 gfL are considered to be indicative of iron deficiency in the general population (1); however, concentrations of ferritin are increased in various conditions such as inflammation, infections, trauma, certain chronic diseases and cancers, and iron overload (2, 3) . Some of these increases are considered to be due to acute-phase reactions. Therefore, in the presence of certain disease states, the cutoff point of normal ferritin values to be used for the diagnosis of iron deficiency must be raised (3). Smoking (current or past) has also been associated with higher plasma/serum ferritin concentrations among various populations (4, 5) , but the significance of this finding is still controversial (6) . In pregnancy, plasma/serum concentrations of ferritin decrease with gestation (7) (8) (9) (10) , but this decrease is prevented to a certain degree by prenatal iron supplementation.
Whether plasma ferritin concentrations accurately represent the body stores of iron during pregnancy is at present unknown (11) .
As part of a double-blind trial to evaluate the effect of zinc supplementation on pregnancy outcome, we monitored plasma ferritin concentrations at 19, 26, 32, and 37 weeks of gestation and delivery in 501 indigent AfricanAmerican women (12). Half of the subjects were randomly assigned to receive an oral zinc supplement (25 mg/day as zinc sulfate) from 19 weeks of gestation until delivery, and the other half received placebo. All subjects were given a daily multivitamin/mineral tablet containing iron (30 mg as ferrous gluconate). The study was approved by the Institutional Review Board of the University of Alabama at Birmingham and a consent form was obtained from each subject.
The numbers of subjects who smoked at the time of blood sampling ranged between 6.5% and 9.7% of the total during pregnancy and was 7.3% at delivery; none of the subjects started to smoke during pregnancy (Fig. 1) . Ferritin was determined by the Magic Ferritin procedure (Ciba Corning Diagnostics, Medfleld, MA), and 125! radioactivity was counted with a Gamma 400 (Beckman Instruments, Palo Alto, CA). Ferritin concentrations in the zinc-supplemented and placebo groups were similar. How-
